Subcutaneous injection: difference between revisions
Diff·revision 24 → 25·22:21, 11 Aug 2025
Difference between revision 24 and revision 25 of Subcutaneous injection. 3 lines changed; the page grew by 653 bytes.
| Revision 24 — 09:55, 19 Jul 2025 SyringeSybille (talk) rm the individualised advice — the article describes, it does not instruct 4,640 bytes ±0 | Revision 25 — 22:21, 11 Aug 2025 CategoryBot (talk) bot: add stub category 5,293 bytes +653 | ||
|---|---|---|---|
| 39 | [[Injection site rotation|Rotation]] between and within sites is the established response. Rotation within a region preserves the region's absorption characteristics while spreading the mechanical insult; rotation between regions changes both. | 39 | [[Injection site rotation|Rotation]] between and within sites is the established response. Rotation within a region preserves the region's absorption characteristics while spreading the mechanical insult; rotation between regions changes both. |
| 40 | 40 | ||
| + | 41 | Transient injection-site reactions — redness, itching, a small wheal — are common with several peptide preparations and generally resolve without intervention. Persistent nodules are a different phenomenon and, for the microsphere formulation of [[Exenatide|exenatide]], are attributable to the polymer matrix rather than to the peptide.{{r|richter2012}} Sterile technique at the point of administration is a separate matter again, treated in the compounding literature.{{r|usp797}} Nothing here is medical advice. | |
| + | 42 | ||
| 41 | == References == | 43 | == References == |
| 42 | {{reflist}} | 44 | {{reflist}} |
| 43 | <ref name="ada2024">American Diabetes Association. "Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 45 | <ref name="ada2024">American Diabetes Association. "Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 44 | <ref name="richter2012">Richter WF, Bhansali SG, Morris ME. "Mechanistic determinants of biotherapeutics absorption following SC administration." ''The AAPS Journal'' 14(3):559–570 (2012). DOI:10.1208/s12248-012-9367-0. PMID 22619043.</ref> | 46 | <ref name="richter2012">Richter WF, Bhansali SG, Morris ME. "Mechanistic determinants of biotherapeutics absorption following SC administration." ''The AAPS Journal'' 14(3):559–570 (2012). DOI:10.1208/s12248-012-9367-0. PMID 22619043.</ref> |
| + | 47 | <ref name="usp797">United States Pharmacopeia, General Chapter <797>, ''Pharmaceutical Compounding — Sterile Preparations''.</ref> | |
| 45 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 48 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 46 | 49 |